BERKELEY HEIGHTS, N.J., Feb. 12, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced the issuance of U.S. Patent No. US 8,349,792 ('792) and European Patent No 2,101,790 ('790). Both patents include claims to combination treatment of sapacitabine, the Company's lead product candidate, with HDAC (histone deacetylase) inhibitors. The patents provide exclusivity until June 2029 and December 2027 respectively.
"The grants of the '792 and '790 patents are important enhancements of sapacitabine's intellectual property estate. They supplement sapacitabine's existing composition of matter, dosing regimen and combination treatment patent protection and support US and EU market exclusivity toward the end of the next decade," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. "We are pursuing a broad intellectual property strategy providing us with a strong foundation to achieve our clinical and commercial objectives for sapacitabine and our other assets. As we continue to enroll SEAMLESS, our pivotal Phase 3 trial of sapacitabine as front-line treatment in elderly patients with acute myeloid leukemia (AML), we look forward to providing additional updates for sapacitabine this year, including Phase 2 data in myelodysplastic syndromes (MDS), AML preceded by MDS, and solid tumors."
The two patents include claims to combinations of sapacitabine and HDAC inhibitors, pharmaceutical compositions comprising sapacitabine and HDAC inhibitors, and methods of treatment using such compositions of proliferative disorders including leukemias, lymphomas, and lung cancer. HDAC inhibitors specifically claimed include belinostat (PXD101), dacinostat (LAQ824), entinostat (MS-275), mocetinostat (MGCD0103), pracinostat (SB939), romidepsin (depsipeptide), sodium butyrate, sodium valproate, tacedinaline (CI-994, PD-123654, GOE-5549, acetyldinaline), trichostatin A, vorinostat (SAHA or suberoylanilide hydramic acid), and valproic acid. Cyclacel published preclinical model data in 2010 demonstrating that sapacitabine works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in vitro and in vivo.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV